L. Montero. Carrera 16# , Consultorio 303, Santafe de Bogotd, D.C., Colombia
|
|
- Imogen Jordan
- 6 years ago
- Views:
Transcription
1 Journal of Antimicrobial Chemotherapy (1996) 37, Suppl. C, A comparative study of the efficacy, safety and tolerability of azithromycin and cefaclor in the treatment of children with acute skin and/or soft tissue infections L. Montero Carrera 16# , Consultorio 303, Santafe de Bogotd, D.C., Colombia An open, multicentre study was carried out in 200 paediatric patients between 6 months and 12 years of age with skin and/or soft tissue infections (mild-to-moderate dermatological conditions and abscesses) to compare the efficacy and safety of azithromycin and cefaclor oral suspensions. Patients were randomly assigned to receive either azithromycin (lomg/kg once daily for 3 days) or cefaclor (20mg/kg/day in three divided doses for 10 days). The clinical efficacy of both treatments was comparable: 92/98 (94%) of the evaluable azithromycin patients were cured or improved as were 93/98 (95%) of those treated with cefaclor. Before treatment, 74 pathogens were isolated from 60 of the azithromycin- and 80 pathogens from 66 of the cefaclor-treated patients. In the azithromycin group, 70/74 (95%) pathogens were eradicated, as were 79/80 (99%) pathogens in the cefaclor group. All 200 patients were evaluable for safety analyses. Both drugs were well tolerated, with a low incidence of side-effects: 3/100 (3%) in the azithromycin group and 2/100 (2%) in the cefaclor group. No patient in either treatment group withdrew from the study because of adverse events. In conclusion, azithromycin is as effective and as well tolerated as cefaclor in the treatment of children with skin and/or soft tissue infections. Introduction Skin and soft tissue infections are common, unpleasant and may become dangerous if left untreated. The most common pathogens are Staphylococcus aureus, Streptococcus pyogenes and Streptococcus agalactiae (Shanson, 1989). Many antibiotics have been used to treat these infections, but their success has been limited by drug resistance or by adverse reactions. Newer antibiotics have shown improved efficacy and safety profiles, but optimal therapy has not yet been defined. Several reports have confirmed the clinical efficacy and wide antimicrobial spectrum of the azalide azithromycin in the treatment of skin and soft tissue infections. Against Gram-positive organisms azithromycin has a spectrum of activity similar to erythromycin (Retsema et al., 1987), but it is substantially more potent in vitro against several important pathogens including /?-haemolytic streptococci of groups C, F and G (Chin et al., 1987). Against Group A and B /?-haemolytic streptococci, azithromycin is as effective as erythromycin in vitro but more effective than cephalexin or cefaclor. In a mouse model of skin infection with S. pyogenes, azithromycin proved to be more effective than clarithromycin or roxithromycin while erythromycin had no effect /96/37CI $12.00/ The British Society for Antimicrobial Chemotherapy
2 126 L. Montero (Pechere, 1994). In other animal models of infection, azithromycin was effective against established tissue infections induced by Salmonella enteritidis (liver and spleen) and S 1. aureus (thigh muscle); erythromycin failed against both infections (Girard el al., 1987). The objectives of the present study were to determine the efficacy and safety of a 3-day course of once-daily azithromycin compared with a 10-day course of cefaclor (three times daily) in the treatment of children with acute skin and/or soft tissue infections. Study design Patients and methods Two hundred children (6 months-12 years) with acute skin and/or soft tissue infectionsincluding abscesses, furuncles, impetigo, pyoderma, cellulitis, infected wounds, scabies with secondary infection and skin ulcersentered this multicentre, open, comparative study. The study was carried out at centres in Colombia, Guatemala, Panama and South Africa. At the pretreatment assessment within 24 h of study drug administration (visit 1, day 1), informed consent was obtained from each patient's parent or legal guardian. A medical history was recorded and a physical examination was performed on each patient before starting antibiotic therapy. To facilitate comparison of signs and symptoms (fever, malaise, pain/tenderness, erythema, swelling, induration, visible pus, exudate, crusting and other specified signs or symptoms) these were graded on a four-point scale: 0 = absent; 1 = mild; 2 = moderate; and 3 = severe. Wherever possible, material was taken for microbiological examination. Blood samples were obtained for haematological and biochemical evaluation, and urinalysis was performed. Other laboratory tests were performed only when indicated. Patients were excluded from the study if they satisfied any of the exclusion criteria shown in Table I. On day 35 of the study (visit 2), patients were examined for signs and symptoms of infection compared with baseline and, in addition, compliance with drug therapy and side-effects were recorded. Where appropriate, material was obtained from the infection site for culture of pathogens and determination of their susceptibility to antibacterial drugs. The final evaluation was undertaken on day after the start of treatment (visit 3). In addition to the assessments carried out at visit 2, laboratory safety tests were repeated. Treatment Patients were randomly assigned in a 1:1 ratio to receive either azithromycin (cherryor banana-flavoured suspension containing 200 mg azithromycin/5 ml) or cefaclor (250 mg/5 ml) oral suspension. Azithromycin was administered once daily at a dose of 10 mg/kg for 3 days 1 h before or 2 h after a meal. Cefaclor was administered at a total daily dosage of 20 mg/kg in divided doses 8 hourly, for 10 days, irrespective of meal times.
3 Azithromycin in skin infections 127 Evaluations Clinical efficacy was classified as: 'cure' (disappearance of all pretreatment signs and symptoms of infection); 'improvement' (improvement in, or partial disappearance of, pretreatment signs and symptoms; or 'failure' (no change in, or worsening of, signs and symptoms). Bacteriological efficacy was categorized as 'eradication' (complete elimination of pretreatment pathogens or unavailability of culturable material); 'partial eradication' (eradication of some, but not all, of the pretreatment pathogens if multiple pathogens were initially isolated); 'persistence' (persistence of pretreatment pathogen(s)) or 'superinfection' (appearance of one or more new pathogen(s) requiring treatment with another antibiotic and the presence of signs and symptoms of infection, irrespective of whether the pretreatment pathogen(s) were eradicated). Any adverse events occurring during the study were recorded and classified as mild, moderate, or severe. The investigator was also requested to record the relationship between adverse events and drug therapy as 'yes', 'no', or 'uncertain/unknown'. All results outside the range of normal values in laboratory parameters were recorded. Whenever possible, tests showing abnormal values were repeated and patients demonstrating clinically meaningful abnormalities or changes in laboratory parameters were monitored until reversion to pretreatment values or resolution of the problem. Data analysis Demographic characteristics and predisposing factors were compared between treatment groups using the y} test for categorical data, Student's /-test for continuous variables, or non-parametric statistical techniques as appropriate. Results There were no significant differences between the two treatment groups in any of the demographic characteristics (Table II). Clinical efficacy Of the 100 children enrolled in each treatment group, 98 were evaluable for clinical efficacy in the azithromycin group and 98 in the cefaclor group. The reason for the Table I. Patient exclusion criteria Treatment with another antibiotic within 72 h before enrolment unless there was documented failure of the other antimicrobial therapy Previous treatment with azithromycin Terminal illness or other condition precluding completion and evaluation of study drug therapy Known hypersensitivity to azithromycin, macrolides, or penicillins/cephalosporins Treatment with any investigational drug within one month before enrolment Infections requiring treatment with another antimicrobial agent in addition to the study drug Concurrent treatment with ergotamine or digitalis glycosides Chronic diarrhoeal disease or other gastrointestinal condition potentially affecting study drug absorption. Isolation of pathogen(s) resistant to the study drug
4 128 L. Montero Table II. Demographic data of 200 children with acute skin and/or soft tissue infections Gender male female Age (years) mean ± S.D. range Weight (kg) mean ± S.D. range Height (cm) mean ± S.D. range Ethnic origin white black other* Azithromycin (n = 100) 49 (49%) 51 (51%) 5.5 ± ± ± (36%) 19(19%) 45 (45%) Cefaclor (n = 100) 57 (57%) 43 (43%) 5.7 ± ± ± (33%) 20 (20%) 47 (47%) "Comprises azithromycin: mestizo 19, mixed 12, other 14 Cefaclor: mestizo 20, mixed 13, other 14. exclusion of all four of these patients from clinical evaluation was loss to follow-up. There were no significant between-group differences in clinical efficacy: at visit 3, 92/98 (94%) of the azithromycin patients were considered cured or improved, as were 93/98 (95%) of those treated with cefaclor (Table III). Considering individual conditions, cefaclor failed in 1/13 (8%) cases of pyoderma, 2/51 (4%) cases of impetigo and 2/18 (11%) cases of cellulitis, whereas in the azithromycin group, treatment failures were observed in 3/44 (7%) of cases of impetigo and 3/16 (19%) of cases of cellutitis (Table III). Table III. Paediatric patients cured/improved or failing with azithromicin or cefaclor therapy Primary diagnosis Abscess Cellulitis Furuncle Impetigo Infected wound Pyoderma Scabies- Skin ulcer Total No. of patients (%) azithromycin cefaclor cured/improved failed cured/improved 7/7(100%) 13/16(81%) 4/4(100%) 41/44(93%) 2/2 (100%) 21/2 2/2(100%) 2/2 (100%) 92/98 (94%) 0/7 (0%) 3/16(19%) 0/4 (0%) 3/44 (7%) 0/21 (14%) 6/98 (6%) 7/7 (100%) 16/18(89%) 7/7 (100%) 49/51 (96%) 12/13(92%) 2/2 (100%) 93/98 (95%) failed 0/7 (0%) 2/18(11%) 0/7 (0%) 2/51 (4%) 1/13(8%) 5/98 (5%) With secondary bacterial infection.
5 Azithromycin in skin infections 129 Table IV. Bacteriological efficacy of azithromycin and cefaclor in children with skin/soft tissue infections Treatment/organism No. of isolates No. ( eradicated %) persisted' Azithromycin S. aureus S. pyogenes Viridans streptococci Staphylococcus epidermidis Streptococci group G E. agglomerans E. cloacae Total (98%) 18(95%) 70 (95%) 1 (2%) 1 (5%) 4 (5%) Cefaclor S. aureus S. pyogenes Viridans streptococci Total (98%) 20(100%) 79 (99%) 1 (2%) 1(1%) 'All; pathogens isolated at baseline were susceptible to azithromycin (disc diffusion zone >18mm; MIC <2mg/L). Bacteriological efficacy Seventy-four pathogens were isolated from 60 of the azithromycin-treated patients and 80 pathogens from 66 of the cefaclor-treated patients. In the azithromycin group, 70/74 (95%) pathogens were eradicated, as were 79/80 (99%) pathogens in the cefaclor group (Table IV). The four failures in the azithromycin group were in patients with impetigo infected with 5. aureus, S. pyogenes, Enterobacter agglomerans and Enterobacter cloacae. The one failure in the cefaclor group was in a patient with pyoderma infected with S. aureus. Safety All 200 patients were evaluable for safety analyses. Both drugs were well tolerated, with a low incidence of side-effects: 3/100 (3%) in the azithromycin group and 2/100 (2%) in the cefaclor group. The side-effects reported in this study were all mild dermatological conditions (pruritus, rash or urticaria) and abscess, except for one patient who experienced a moderate papular rash that was only possibly due to azithromycin. No patient in either treatment group withdrew from the study because of side-effects. Discussion Azithromycin has been compared with several antibiotics, including erythromycin, cloxacillin and cephalexin, in the treatment of infections of the skin and soft tissues in adults (Kiani, 1994). All studies reported to date have shown that azithromycin is at least equivalent to these antimicrobial agents in terms of clinical cure and improvement rates and also in the eradication of pathogenic bacteria (Kiani, 1994). However,
6 130 L. Montero azithromycin has the advantages of a simpler dosage regimen (once daily) compared with antibiotics such as cephalosporins (most of which have to be taken twice or three-times daily) and also a shorter duration of therapy (3-5 days with azithromycin compared with 7-10 days for cephalosporins, Kiani, 1994). Initial comparative clinical trials in adult patients with infections of the skin and soft tissues studied azithromycin at a dosage of 500 mg on day 1, followed by 250 mg once daily for the next 4 days. These studies confirmed that azithromycin was as effective as 500 mg cloxacillin administered four times daily for 7 days (Daniel et al., 1991), 500 mg cephalexin given twice daily for 10 days (Herbert, 1990; Treadway, 1990; Kiani, 1991; Mallory, 1991), or 500 mg erythromycin taken four times daily for 7 days (Daniel et al., 1991). The high incidences of satisfactory clinical response and bacteriological eradication were similar for azithromycin and the comparative agents. Later studies showed that azithromycin could be administered for only 3 days, at a dosage of 500 mg once daily, and still produce the same high efficacy rates in patients with skin and soft tissue infections. Two prospective randomized studies (one in adults and the other in both adults and children) with skin and skin structure infections showed that once-daily azithromycin at a dosage of 500 mg (10 mg/kg in children) for 3 days was as effective as dicloxacillin at a dosage of 250 mg ( mg/kg/day in children) administered four times daily for 7 days (Arias-Orozco et al., 1991; Amaya-Tapia et al., 1993). An open, randomized, multicentre trial in 110 children (2-12 years old) with clinically diagnosed acute skin and soft tissue infections showed that oral azithromycin (10 mg/kg/day) administered once daily for only 3 days was as effective as dicloxacillin ( mg/kg/day) or flucloxacillin ( mg/day) four times daily for 7 days (Rodriguez-Solares et al., 1993). In common with other investigations, the present study has shown that azithromycin is as effective as comparative antibiotics in eradicating the bacteria causing skin and soft tissue infections and in achieving clinical cure or improvement. The most common pathogens isolated from our patients were S. pyogenes and 5. aureus, as in other studies, and both azithromycin and cefaclor were equally effective against these and the other pathogens isolated. Both drugs were very well tolerated, with few adverse events. There were, however, significant differences in the treatment regimens of both antibiotics, with advantages in favour of azithromycin. The once-daily dosing of azithromycin and the short (3-day) duration of treatment are likely to be associated with better patient compliance than three-times-daily treatment with cefaclor and the longer (10-day) dosing duration. In conclusion, azithromycin is as effective and as well tolerated as cefaclor for the treatment of infections of skin or soft tissues in children, and has the advantage of a shorter, simpler therapeutic regimen. References Amaya-Tapia, G., Aguirre-Avalos, G., Andrade-Villanueva, J., Peredo-Gonzalez, G., Morfin-Otero, R., Esparza-Ahumada, S. et al. (1993). Once-daily azithromycin in the treatment of adult skin and skin-structure infections. Journal of Antimicrobial Chemotherapy 31, Suppl. E, Arias-Orozoco, M., Andrade-Villanueva, J., Amaya-Tapia, G., Plasccncia-Hernandez, A. & Rodriguez-Noriega, E. (1991). Safety and efficacy of azithromycin (AZI) and dicloxacillin (DICLO) in the treatment of skin and skin structure infections (SSSI). In Program and
7 Azithromycin in skin infections 131 Abstracts of the Thirty-First Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, American Society for Microbiology, Washington, DC. Chin, N. X., Saha, G., Labthavikul, P. & Neu, H. C. (1987). The in vitro activity of CP-62,993, a new 15-membered ring macrolide compared with that of other oral antibiotics. In Program and Abstracts of the Twenty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, American Society for Microbiology, Washington, DC. Daniel, R. & the European Azithromycin Study Group. (1991). Azkhiomycin, erythromycin and cloxacillin in the treatment of infections of skin and associated soft tissues. Journal of International Medical Research 19, Girard, A. E., Girard, D., English, A. R., Gootz, T. D., Cimochowski, C. R., Faiella, J. A. et al. (1987). Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrobial Agents and Chemotherapy 31, Herbert, A. (1990). Azithromycin in the treatment of skin and skin structure infections: a multicenter, double-blind, double-dummy trial employing cephalexin (Reflex) as a comparative agent. Clinical Research 38, 929A. Kiani, R. (1991). Double-blind, double-dummy comparison of azithromycin and cephalexin in the treatment of skin and skin structure infections. European Journal of Clinical Microbiology and Infectious Diseases 10, Kiani, R. (1994). Azithromycin in the treatment of infections of skin and associated tissues. Reviews of Contemporary Pharmacotherapeutics 5, Mallory, S. B. (1991). Azithromycin compared with cephalexin in the treatment of skin and skin structure infections. American Journal of Medicine 91, Suppl. 3A, Pechere, J.-C. (Ed.) (1994). Comparative activity of antibiotics against group A streptococci in experimental infections. In Acute Bacterial Pharyngitis, pp Cambridge Medical Publications, Worthing. Retsema, J., Girard, A., Schelkly, W., Manousos, M., Anderson, M., Bright, G. et al. (1987). Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against Gram-negative organisms. Antimicrobial Agents and Chemotherapy 31, 1939-^7. Rodriguez-Solares, A., Perez-Gutierrez, F., Prosperi, J., Milgram, E. & Martin, A. (1993). A comparative study of the efficacy, safety and tolerance of azithromycin, dicloxacillin and flucloxacillin in the treatment of children with acute skin and skin-structure infections. Journal of Antimicrobial Chemotherapy 31, Suppl. E, Shanson, D. C. (1989). Microbiology in Clinical Practice, 2nd edn, pp Wright, London.
JAC Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections
Journal of Antimicrobial Chemotherapy (1998) 41, Suppl. B, 69 73 JAC Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections G. Tatsis*, G.
More informationClarithromycin versus penicillin in the treatment of streptococcal pharyngitis
Journal of Antimicrobial Chemotherapy (1991) 27, Suppl. A, 67-74 Clarithromycin versus penicillin in the treatment of streptococcal pharyngitis Joseph H. Levenstein* South Africa Academy of Family Practice,
More informationAn open comparative study of azithromycin versus cefaclor in the treatment of patients with upper respiratory tract infections
Journal of Antimicrobial Chemotherapy (1996) 37, Suppl. C, 71-81 An open comparative study of azithromycin versus cefaclor in the treatment of patients with upper respiratory tract infections B. O'Doherty
More informationFusidic acid and erythromycin in the treatment of skin and soft tissue infection: a double blind study Wall A R, Menday A P
Fusidic acid and erythromycin in the treatment of skin and soft tissue infection: a double blind study Wall A R, Menday A P Record Status This is a critical abstract of an economic evaluation that meets
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 October 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 October 2006 CUBICIN 350 mg (daptomycin), powder for perfusion solution Box of 1 bottle (CIP code: 567 219-3) CUBICIN
More informationPFIZER INC. Study Initiation Date and Completion Dates: 09 March 2000 to 09 August 2001.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationDrug Class Review on Macrolides
Drug Class Review on Macrolides Preliminary Scan Report 5 July 2014 Last Report: Original August 2006 The purpose of reports is to make available information regarding the comparative clinical effectiveness
More informationCeftizoxime in the treatment of infections in patients with cancer
Journal of Antimicrobial Chemotherapy (98), Suppl. C, 67-73 Ceftizoxime in the treatment of infections in patients with cancer V. Fainstein, R. Bolivar,. Elting, M. Valdivieso and G. P. Bodey Department
More informationPFIZER INC. Study Initiation Date and Completion Dates: Information not available (Date of Statistical Report: 16 May 2004)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationALTARGO TM Retapamulin. QUALITATIVE AND QUANTITATIVE COMPOSITION Retapamulin 10 mg per gram (1% w/w)
ALTARGO TM Retapamulin QUALITATIVE AND QUANTITATIVE COMPOSITION Retapamulin 10 mg per gram (1% w/w) PHARMACEUTICAL FORM Ointment. CLINICAL PARTICULARS Indications ALTARGO (retapamulin) 1% ointment is indicated
More informationEvaluation of Cefuroxime Axetil and Cefadroxil Suspensions
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1992, p. 1614-1618 0066-4804/92/081614-05$02.00/0 Copyright 1992, American Society for Microbiology Vol. 36, No. 8 Evaluation of Cefuroxime Axetil and Suspensions
More informationStudy design: The study was a multicentre, prospective, randomised, doubleblind, parallel-group study.
2 11 September 1.997 Page 9 of161 SYNOPSIS FUT 9403 INT : FUCIDIN VERSUS ERYTHROMYCIN IN SKIN AND SOFT TISSUE INFECTION. A comparison of sodium fusidate tablets 250mg bd (Fucidin tablets) and erythromycin
More informationAerobic gram-positive microorganisms Staphylococcus aureus, Streptococcus agalactiae, Streptococcus pneumonia, Streptococcus pyogenes
AZIMEX Composition Each 5 ml contains Azithromycin (as dihydrate) 200 mg Powder Action Azithromycin acts by binding to the 50S ribosomal subunit of susceptible microorganisms and, thus, interfering with
More informationALTARGO. Retapamulin. Retapamulin 10 mg per gram (1% w/w)
ALTARGO Retapamulin 1. QUALITATIVE AND QUANTITATIVE COMPOSITION Retapamulin 10 mg per gram (1% w/w) 2. PHARMACEUTICAL FORM Ointment 3. CLINICAL PARTICULARS 3.1 Indications Retapamulin is indicated for
More informationZINEX. Composition Each tablet contains Cefuroxime (as axetil) 250 or 500 mg
ZINEX Composition Each tablet contains Cefuroxime (as axetil) 250 or 500 mg Tablets Action Cefuroxime axetil owes its bactericidal activity to the parent compound cefuroxime. Cefuroxime is a well-characterized
More informationCefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefotaxime Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationBeta-lactamase production should have no effect on Azithromycin activity.
AZIMEX Composition Azimex 250 Capsules Each capsule contains Azithromycin (as dihydrate) 250 mg Capsules & Powder Azimex 500 mg Capsules Each capsule contains Azithromycin (as dihydrate) 500 mg Azimex
More informationESCMID Online Lecture Library. by author
Hospital Universitario Virgen Macarena, Seville New drugs against MRSA and VRE L. Eduardo López Cortés Seville, 8th July Tedizolid Oxazolidinone Ceftaroline // Ceftobiprole 5 th gen cephalosporin Overview
More informationAppropriate Use of Antibiotics for the Treatment of Acute Upper Respiratory Tract Infections in Adults
Appropriate Use of Antibiotics for the Treatment of Acute Upper Respiratory Tract Infections in Adults Kyong Ran Peck, M.D. Division of Infectious Diseases Sungkyunkwan University School of Medicine, Samsung
More informationORIGINAL INVESTIGATION. Comparison of Short-Course (5 Days) and Standard (10 Days) Treatment for Uncomplicated Cellulitis
ORIGINAL INVESTIGATION Comparison of Short-Course (5 Days) and Standard (10 Days) Treatment for Uncomplicated Cellulitis MAJ Matthew J. Hepburn, MC, USA; COL David P. Dooley, MC, USA; MAJ Peter J. Skidmore,
More informationComparative Efficacy and Safety Evaluation of Cefaclor VS Amoxycillin + Clavulanate in Children with Acute Otitis Media (AOM)
Special Article Comparative Efficacy and Safety Evaluation of Cefaclor VS Amoxycillin + Clavulanate in Children with Acute Otitis Media (AOM) Mukesh Aggarwal, Ramanuj Sinha 1, M. Vasudeva Murali 2, Prita
More informationMesporin TM. Ceftriaxone sodium. Rapid onset, sustained action, for a broad spectrum of infections
Ceftriaxone sodium Rapid onset, sustained action, for a broad spectrum of infections 1, 2, 3 Antibiotic with a broad spectrum of activity Broad spectrum of activity against gram-positive* and gram-negative
More informationBeta-lactamase production should have no effect on Azithromycin activity.
AZIMEX Composition Azimex 250 Capsules Each capsule contains Azithromycin (as dihydrate) 250 mg Capsules Azimex 500 mg Capsules Each capsule contains Azithromycin (as dihydrate) 500 mg Action Azithromycin
More informationGROUP A STREPTOCOCCUS (GAS) INVASIVE
GROUP A STREPTOCOCCUS (GAS) INVASIVE Case definition CONFIRMED CASE Laboratory confirmation of infection with or without clinical evidence of invasive disease: isolation of group A streptococcus (Streptococcus
More informationPhenoxymethyl penicillin versus co-amoxiclav in the treatment of acute streptococcal pharyngitis, and the role of /Mactamase activity in saliva
Journal of Antimicrobial Chemotherapy (1996) 7, 1-18 Phexymethyl penicillin versus co-amoxiclav in the treatment of acute streptococcal pharyngitis, and the role of /Mactamase activity in saliva R. S.
More informationMacrolides & Ketolides. Objectives. Protein Synthesis
Macrolides & Ketolides Elizabeth D. Hermsen, Pharm.D. Infectious Diseases Research Fellow University of Minnesota College of Pharmacy bjectives Participant should be able to explain macrolide/ketolide
More informationChoosing an appropriate antimicrobial agent. 3) the spectrum of potential pathogens
Choosing an appropriate antimicrobial agent Consider: 1) the host 2) the site of infection 3) the spectrum of potential pathogens 4) the likelihood that these pathogens are resistant to antimicrobial agents
More informationNew guidelines for the antibiotic treatment of streptococcal, enterococcal and staphylococcal endocarditis. D. C. Shanson
Journal of Antimicrobial Chemotherapy (1998) 42, 292 296 New guidelines for the antibiotic treatment of streptococcal, enterococcal and staphylococcal endocarditis JAC D. C. Shanson Microbiology Department,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationMultiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers
Journal of Antimicrobial Chemotherapy (1996) 37, 955-963 Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers Renli Teng, Theodore E. Liston and Stephen C. Harris Central Research
More informationTHE USE OF THE PENICILLINASE-RESISTANT
Therapeutic problems THE USE OF THE PENICILLINASE-RESISTANT PENICILLIN IN THE PNEUMONIAS OF CHILDREN MARTHA D. Yow, MARY A. SOUTH AND CHARLES G. HESS From the Department of Pediatrics, Baylor University
More informationThe absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension
Journal of Antimicrobial Chemotherapy (1996) 37, Suppl. C, 37-44 The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension G. Foulds', D. R.
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationSTUDY OF IMPETIGO AND THE RESISTANCE PATTERN OF THE ISOLATES TO VARIOUS ANTIBIOTICS
STUDY OF IMPETIGO AND THE RESISTANCE PATTERN OF THE ISOLATES TO VARIOUS ANTIBIOTICS Abstract Pages with reference to book, From 129 To 132 Aqeel Ahmad, Khursheed Ali Khan ( Department of Microbiology,
More informationTOUGH ON IMPETIGO GENTLE ON THE1 PATIENT. Demonstrated efficacy and safety1. New treatment option now available!
New treatment option now available! TOUGH ON IMPETIGO GENTLE ON THE1 PATIENT Demonstrated efficacy and safety1 Home Efficacy Safety Convenience (ozenoxacin) is indicated for the topical treatment of impetigo
More informationAmoxitid 125 Suspension Each teaspoonful (5 ml) contains Amoxicillin (as trihydrate) 125 mg.
AMOXITID Composition Amoxitid 250 Capsules Each capsule contains Amoxicillin (as trihydrate) 250 mg. Capsules & Suspension Amoxitid 500 Capsules Each capsule contains Amoxicillin (as trihydrate) 500 mg.
More informationA comparative trial of Azithromycin versus Doxycycline for the treatment in Rickettsial Fever
Original article A comparative trial of Azithromycin versus Doxycycline for the treatment in Rickettsial Fever Dr Deo Bhushan, Dr Jadhav Jayashree, DR Nigavekar P V, DR Himanshu Kumar Department of Pediatrics,
More informationAbstract. Introduction
ORIGINAL ARTICLE 10.1111/j.1469-0691.2009.02718.x Single-dose extended-release oral azithromycin vs. 3-day azithromycin for the treatment of group A b-haemolytic streptococcal pharyngitis/ tonsillitis
More informationPAEDIATRIC ACUTE CARE GUIDELINE. Impetigo. This document should be read in conjunction with this DISCLAIMER
Princess Margaret Hospital for Children PAEDIATRIC ACUTE CARE GUIDELINE Impetigo Scope (Staff): Scope (Area): All Emergency Department Clinicians Emergency Department This document should be read in conjunction
More information(NATO STANAG 2122, CENTO STANAG 2122, SEATO STANAG 2122)
(NATO STANAG 2122, CENTO STANAG 2122, SEATO STANAG 2122) Bacteria Bacteria are microscopic, single-celled forms of plant life, containing no chlorophyll. They live on the skin, on the surface of the stratum
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active Ingredient Cefradine Ph Eur 3 PHARMACEUTICAL FORM Capsules. 4 CLINICAL PARTICULARS Per
More informationIntroduction. Crowded environments where the air is re-circulated can often be heavily infected with unseen germs and viruses.
Introduction The continued increase in urbanisation,, population growth and global travel means germs and viruses can spread faster and further than ever before. Air, sea, rail and road travel have never
More informationSetting The setting was secondary care. The economic study was carried out in the USA.
Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia Paladino J A, Gudgel L D, Forrest A, Niederman
More informationStaphylococci and streptococci
Staphylococci and streptococci Prof. Marianna Murdjeva, MD, PhD Dept. Microbiology and Immunology Medical University Plovdiv Lecture course in microbiology for English-speaking medical students Staphylococci
More informationTwice daily ceftriaxone therapy for serious bacterial infections in children
Journal of Antimicrobial Chemotherapy (1984) 13, 511-516 Twice daily ceftriaxone therapy for serious bacterial infections in children Tasnee Chonmaitree*, Blaise L. Congenif, Jose Munoz+, Tamara A. Rakusan*,
More informationCefuroxime iv Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefuroxime iv Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Fucidin 20 mg/g ointment 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One gram of ointment contains 20 mg sodium fusidate For a full list
More informationProphylactic and Therapeutic Activities of Azithromycin in a Mouse Model of Pneumococcal Pneumonia
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 1991, p. 124-128 66-484/91/6124-5$2./ Copyright 1991, American Society for Microbiology Vol. 35, No. 6 Prophylactic and Therapeutic Activities of Azithromycin
More informationRespiratory tract infections. Krzysztof Buczkowski
Respiratory tract infections Krzysztof Buczkowski Etiology Viruses Rhinoviruses Adenoviruses Coronaviruses Influenza and Parainfluenza Viruses Respiratory Syncitial Viruses Enteroviruses Etiology Bacteria
More informationStudy on Incidence of Antibiotic Associated Diarrhoea in General Paediatric Ward
HK J Paediatr (new series) 2002;7:33-38 Study on Incidence of Antibiotic Associated Diarrhoea in General Paediatric Ward CM HUI, K TSE Abstract Objective: To estimate the incidence rate and risk factors
More informationAzithromycin for the treatment of acne
Pharmacology and therapeutics Azithromycin for the treatment of acne Adolfo C. Fernandez-Obregon, MD From the Hudson Dermatology & Skin Center, Hoboken, New Jersey Abstract Background Acne affects a large
More informationWARNING: TENDON EFFECTS and EXACERBATION OF MYASTHENIA GRAVIS
DECLESAU (dergrafloxacin) tablets, for oral use DECLESAU (dergrafloxacin) injection, solution for intravenous use WARNING: TENDON EFFECTS and EXACERBATION OF MYASTHENIA GRAVIS Fluoroquinolones, including
More informationoftioconazole Cream 1% versus
The Journal ofinternational Medical Research 1987; IS: 2~3l Comparative and Non-comparative Studies ofthe Efficacy and Tolerance oftioconazole Cream 1% versus Another Imidazole and/or Placebo in Neonates
More informationClinical Comparison of Cefotaxime with Gentamicin plus Clindamycin in the Treatment of Peritonitis and Other Soft-Tissue Infections
REVIEWS OF INFECTIOUS DISEASES. VOL. 4, SUPPLEMENT. SEPTEMBER-OCTOBER 982 982 by The University of Chicago. All rights reserved. 062-0886/82/0405-022$02.00 Clinical Comparison of with Gentamicin plus Clindamycin
More informationPHARMACOLOGICAL CLASSIFICATION A Ophthalmic preparations with antibiotics and/or sulphonamides
Page 1 of 6 SCHEDULING STATUS Schedule 4 PROPRIETARY NAME AND DOSAGE FORM ZYMAR eye drops (ophthalmic solution) COMPOSITION Each ml contains 3 mg gatifloxacin (0,3 % m/v) Preservative: benzalkonium chloride
More informationRochester Patient Safety C. difficile Prevention Collaborative: Long Term Care Antimicrobial Stewardship (funded by NYSDOH)
Rochester Patient Safety C. difficile Prevention Collaborative: Long Term Care Antimicrobial Stewardship (funded by NYSDOH) Clinical Practice Guideline* for the Diagnosis and Management of Acute Bacterial
More informationStreptococci facultative anaerobe
THE GENUS STREPTOCOCCUS The genus Streptococcus obtains Gram-positive cocci, nonmotile, nonsporeforming, arranged mostly in chains or in pairs. Most species are facultative anaerobes. Some of streptococci
More informationSUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT Fusidic Acid 2% Cream SUMMARY OF PRODUCT CHARACTERISTICS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 2 % cream. Each gram contains 20 mg fusidic acid. Excipient(s) with
More informationPRODUCT INFORMATION DICLOCIL. (dicloxacillin sodium) POWDER FOR INJECTION
PRODUCT INFORMATION DICLOCIL (dicloxacillin sodium) POWDER FOR INJECTION NAME OF THE MEDICINE Dicloxacillin sodium is sodium (6R)-6-[3-(2,6-dichlorophenyl)-5-methylisoxazole-4- carboxamido]-penicillanate
More informationDecember 3, 2015 Severe Sepsis and Septic Shock Antibiotic Guide
Severe Sepsis and Septic Shock Antibiotic Guide Surviving Sepsis: The choice of empirical antimicrobial therapy depends on complex issues related to the patient s history, including drug intolerances,
More informationCEFADUR Tablet (Cefadroxil)
Published on: 23 Sep 2014 CEFADUR Tablet (Cefadroxil) Composition CEFADUR-500 Each Film-coated tablet contains Cefadroxil IP equivalent to Cefadroxil anhydrous...500 CEFADUR 125 DT Each dispersible uncoated
More informationDOSAGE FORMS AND STRENGTHS Cream: Each gram contains 10 mg of ozenoxacin (1%) (3).
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use XEPI TM safely and effectively. See full prescribing information for XEPI TM. XEPI TM (ozenoxacin)
More informationEnhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models
Journal of Antimicrobial Chemotherapy (25) 56, 365 37 doi:.93/jac/dki24 Advance Access publication 7 July 25 Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection
More informationEffectiveness of mezlocillin in female genital tract infections
Journal of Antimicrobial Chemotherapy (98) 9, Suppl. A, 9-8 Effectiveness of mezlocillin in female genital tract infections John R. Marshall, Anthony W. Chow* and Tania C. Sorrell** The Departments of
More informationThe McMaster at night Pediatric Curriculum
The McMaster at night Pediatric Curriculum Community Acquired Pneumonia Based on CPS Practice Point Pneumonia in healthy Canadian children and youth and the British Thoracic Society Guidelines on CAP Objectives
More informationReceived 30 March 2005; returned 16 June 2005; revised 8 September 2005; accepted 12 September 2005
Journal of Antimicrobial Chemotherapy (2005) 56, 1047 1052 doi:10.1093/jac/dki362 Advance Access publication 20 October 2005 Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity,
More informationPAEDIATRIC HOSPITAL LEVEL ESSENTIAL MEDICINES LIST CHAPTER 5: DERMATOLOGY NEMLC 30 JUNE 2016
PAEDIATRIC HOSPITAL LEVEL ESSENTIAL MEDICINES LIST CHAPTER 5: DERMATOLOGY NEMLC 30 JUNE 2016 PICTURES OF CONDITIONS: The Paediatric Expert Review Committee (ERC) recommended that the Dermatology Chapter
More informationAzithromycin versus Pivampicillin in the Treatment of Acute Exacerbations of Chronic Bronchitis: a Single-blind, Doubledummy, Multicentre Study
M Nomura, S Kida, J Yamashita The Journal et al. of International Medical Research Endovascular 2000; 28: Embolization 101 110 of Unruptured Vertebral Dissection Azithromycin versus Pivampicillin in the
More informationAffinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED
AAC Accepts, published online ahead of print on February 00 Antimicrob. Agents Chemother. doi:./aac.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationStreptococcal Pharyngitis
Streptococcal Pharyngitis Issues in Infectious Diseases Vol. 3 Series Editors Heinz Zeichhardt Brian W. J. Mahy Berlin Atlanta, GA Streptococcal Pharyngitis Optimal Management Volume Editors Jean Claude
More informationReceived 25 November 2002/Returned for modification 14 February 2003/Accepted 11 April 2003
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 2003, p. 2770 2774 Vol. 47, No. 9 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.9.2770 2774.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationFULL PRESCRIBING INFORMATION: CONTENTS*
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OTIPRIO safely and effectively. See full prescribing information for OTIPRIO. OTIPRIO (ciprofloxacin
More informationProtein Synthesis Inhibitors. Ass Prof. Dr. Naza M. Ali 15 Nov 2018 Lec 8
Protein Synthesis Inhibitors Ass Prof. Dr. Naza M. Ali 15 Nov 2018 Lec 8 These drugs selectively inhibit bacterial protein synthesis. The selectivity is due to the differences between bacterial and human
More informationTreatment of febrile neutropenia in patients with neoplasia
Treatment of febrile neutropenia in patients with neoplasia George Samonis MD, PhD Medical Oncologist Infectious Diseases Specialist Professor of Medicine The University of Crete, Heraklion,, Crete, Greece
More informationCubicin A Guide to Dosing
Cubicin A Guide to Dosing Cubicin (Daptomycin) powder for solution for injection or infusion Indications (see SmPC) 1 : Cubicin is indicated for the treatment of the following infections (see sections
More informationPRODUCT INFORMATION DICLOCIL
PRODUCT INFORMATION DICLOCIL (dicloxacillin sodium) CAPSULES NAME OF THE DRUG Dicloxacillin sodium is sodium (6R)-6-[3-(2,6-dichlorophenyl)-5-methylisoxazole-4- carboxamido]-penicillanate monohydrate;
More informationEMILOK Global. (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated
EMILOK Global (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated granules. Properties: Emilok (omeprazole) belongs to the group of proton pump inhibitors, inhibits both
More informationDrug Class Update with New Drug Evaluation: Topical Antibiotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationVancomycin. A bactericidal drug which acts by inhibiting cell wall synthesis. Active only against gram-positive bacteria, particularly staphylococci.
Vancomycin A bactericidal drug which acts by inhibiting cell wall synthesis. Active only against gram-positive bacteria, particularly staphylococci. Used IV in treating endocarditis caused by methicillin-resistant
More informationClindamycin strep throat dose
Clindamycin strep throat dose User Reviews for Clindamycin. Also known as: Cleocin, Cleocin HCl, Cleocin Pediatric, Cleocin Phosphate, Cleocin Phosphate ADD-Vantage. The following information is. 1 Answer
More informationMRSA: A TEAM APPROACH
Eric Bosley, MD Laura Stadler, MD John MD J h Draus, D MRSA: A TEAM APPROACH PART I: OUTPATIENT ISSUES AND MANAGEMENT NOT REQUIRING I&D OR HOSPITALIZATION Eric L. Bosley, MD, FAAP Pediatric Associates,
More informationEfficacy of Ceftriaxone in Serious Bacterial Infections
ANTIMIROBIAL AGENTS AND HEMOTHERAPY, Mar 1982, p 402-406 0066-4804/82/030402-05$0200/0 Vol 21, No 3 Efficacy of eftriaxone in Serious Bacterial Infections JAY S EPSTEIN, SUSAN M HASSELQUIST, AND GARY L
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Nicef Capsules 250mg / Cefradine Capsules 250mg 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active Ingredient Cefradine Ph Eur 3 PHARMACEUTICAL
More informationCOMMON SKIN INFECTIONS. Sports Medicine
COMMON SKIN INFECTIONS Sports Medicine IMPETIGO IS A SUPERFICIAL BACTERIAL INFECTION CAUSED BY: STREPTOCOCCI OR STAPHYLOCOCCUS AUREUS BOULOUS IMPETIGO IMPETIGO COMES IN TWO FORMS: BOULOUS OR NON- BOULOUS
More informationClinical Policy Title: Strep testing
Clinical Policy Title: Strep testing Clinical Policy Number: 07.01.09 Effective Date: December 1, 2017 Initial Review Date: October 19, 2017 Most Recent Review Date: November 16, 2017 Next Review Date:
More informationGroup B streptococcal infection;. Bacteremia without a focus occurs in 80-85%,. July has been recognised as Group B Strep Awareness Month,.
Group B streptococcal infection;. Bacteremia without a focus occurs in 80-85%,. July has been recognised as Group B Strep Awareness Month,. 12-10-2017 Group B streptococci are uniformly sensitive to penicillin
More informationSynergistic Activity of Azithromycin and Pyrimethamine or
ANTMCROBAL AGNTS AND CHMOTHRAPY, May 199, p. 997-11 66-44/9/5997-5$./ Copyright 199, American Society for Microbiology Vol. 36, No. 5 Synergistic Activity of Azithromycin and Pyrimethamine or Sulfadiazine
More information13/10. Microbiology Bacterial Skin Infections Dr Hani Masaadeh Areej al-arqan
13/10 Microbiology Bacterial Skin Infections Dr Hani Masaadeh Areej al-arqan Salam soul, this is the first Microbiology lecture of this system given by Dr.hani masaadeh. I ll do my best to make it easy
More informationTreatment of serious Pseudomonas infections with azlocillin
Journal of Antimicrobial Chemotherapy (983), Suppl. B, 53-58 Treatment of serious Pseudomonas infections with azlocillin S. Olive, W. J. Mogabgab, B. Holmes, B. Pollock, B. Pauling and R. Beville Tulane
More informationOmnix Tablets / DT / Dry Syrup (Cefixime)
Published on: 22 Sep 2014 Omnix Tablets / DT / Dry Syrup (Cefixime) Composition OMNIX-50 DT Each uncoated dispersible tablet contains: Cefixime, IP, as a trihydrate equivalent to Anhydrous Cefixime...
More informationPRODUCT INFORMATION. CECLOR (cefaclor monohydrate)
PRODUCT INFORMATION CECLOR (cefaclor monohydrate) NAME OF THE DRUG CECLOR (cefaclor monohydrate) CH NH 2 O C H N O N S Cl H 2O O C OH DESCRIPTION CECLOR (cefaclor monohydrate) is a semisynthetic cephalosporin
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Ceporex Syrup 250mg. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Cefalexin 250mg per 5ml (Cetalexin (in granules) 7.80% w/w, Cetalexin
More informationThe score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.
1. NAME OF THE MEDICINAL PRODUCT Avopenin 800 mg film-coated tablets Avopenin 1 g film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Phenoxymethylpenicillin potassium 800 mg or 1 g For a full
More informationClinialTrials.gov Identifier: sanofi-aventis. Sponsor/company: 07/November/2008
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Ceporex Capsules 250mg 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Cefalexin BP 250mg per capsule. 3 PHARMACEUTICAL FORM Capsule. 4 CLINICAL
More informationClinico-etiological study of pyodermas in a tertiary care hospital
Original Research Article Purnachandra Badabagni 1, Shashikant Malkud 2,* 1 Associate Professor, 2 Assistant Professor, Dept. of Dermatology, Venereology and Leprosy, MNR Medical College & Hospital, Sangareddy,
More informationSequential intravenous-oral amoxycillin/clavulanate (Augmentin) therapy in paediatric hospital practice
Journal of Antimicrobial Chemotherapy (987) 9, 385-39 equential intravenous-oral amoxycillin/clavulanate (Augmentin) therapy in paediatric hospital practice Urs B. chaad, Jurg Pfenninger and Joanna Wedgwood-Krucko
More informationPOLICY FOR TREATMENT OF UPPER RESPIRATORY TRACT INFECTIONS
POLICY F TREATMENT OF UPPER RESPIRATY TRACT INFECTIONS Written by: Dr M Milupi, Consultant Microbiologist Date: June 2018 Approved by: Date: July 2018 The Drugs & Therapeutics Committee Implementation
More information